ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

Phase III Cyramza Trial Meets OS Primary Endpoint

September 26, 2014

Reports On AACR Scientific Sessions

May 21, 1976

FDA Moves to Regulate Lab-Developed Tests

August 1, 2014

An Early Look At How NCI Plans To Spend Its Money In 1980

July 7, 1978

NCI Bypass Budget Seeks $3.6 Billion for Fiscal 1995

October 1, 1993

NIH Considering Intramural NRSA, NCI Advisors Not Enthusiastic

February 17, 1984